Evolution of M. bovis BCG Vaccine: Is Niacin Production Still a Valid Biomarker?

Abstract EN

BCG vaccine is usually considered to be safe though rarely serious complications have also been reported, often incriminating contamination of the seed strain with pathogenic Mycobacterium tuberculosis.

In such circumstances, it becomes prudent to rule out the contamination of the vaccine seed.

M.

bovis BCG can be confirmed by the absence of nitrate reductase, negative niacin test, and resistance to pyrazinamide and cycloserine.

Recently in India, some stocks were found to be niacin positive which led to a national controversy and closer of a vaccine production plant.

This prompted us to write this review and the comparative biochemical and genotypic studies were carried out on the these contentious vaccine stocks at the Indian vaccine plant and other seeds and it was found that some BCG vaccine strains and even some strains of M.

bovis with eugenic-growth characteristics mainly old laboratory strains may give a positive niacin reaction.

Most probably, the repeated subcultures lead to undefined changes at the genetic level in these seed strains.

These changing biological characteristics envisage reevaluation of biochemical characters of existing BCG vaccine seeds and framing of newer guidelines for manufacturing, production, safety, and effectiveness of BCG vaccine.